#For clinicians

Written for prescribing clinicians, with full citation chains.

A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.

FLOW established kidney-outcome evidence for semaglutide in diabetic CKD. A translational review explains why SGLT2 combination trials are next.

A Canadian analysis estimated how far GLP-1 receptor agonist prices would need to fall to become cost-effective.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

One patient taking tirzepatide completed 17 ECT sessions without complications, but the case report cannot establish a safe protocol.

A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.

A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.

A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.

A matched UK cohort linked tirzepatide use to lower weight, HbA1c and insulin needs in type 1 diabetes, but it was not randomized.

A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.

A pooled STEP analysis found more gallbladder events with semaglutide 2.4 mg than placebo, but the absolute event rate remained low.

A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.